We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

BioTek

BioTek Instruments, Inc., designs, manufactures, and distributes life science instrumentation. Its product line inclu... read more Featured Products: More products

Download Mobile App




Modular Design of New Microplate Reader Encourages Modification and Upgrades

By LabMedica International staff writers
Posted on 25 Aug 2014
Print article
BioTek Instruments\' Synergy HTX Multi-Mode Microplate Reader
The Synergy HTX Multi-Mode Microplate Reader (Photo courtesy of Agilent - BioTek)
Life science and biotech researchers now have available a state-of-the-art modular microplate reader with a wide range of capabilities from UV-visual absorbance to bottom fluorescence and luminescence.

The new BioTek Instruments, Inc. (Winooski, VT, USA) Synergy HTX Multi-Mode Microplate Reader is an entry-level multimode reader that automates UV-visual absorbance, fluorescence, luminescence, and AlphaScreen/AlphaLISA assays in 6- to 384-well microplates that can be delivered in samples as small as two microliters.

AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay Screen) is versatile assay technology developed to measuring analytes using a homogenous protocol. This technology is an example of a bead-based proximity assay and was developed from a diagnostic assay technology known as LOCI (Luminescent Oxygen Channeling Assay) where singlet oxygen molecules, generated by high energy irradiation of donor beads, travel over a constrained distance of approximately 200 nanometers) to acceptor beads. This results in excitation of a cascading series of chemical reactions, ultimately causing generation of a chemiluminescent signal. Recently, the basic AlphaScreen technology was extended in that the chemistry of the acceptor bead was modified such that emitted light is more intense and spectrally defined, thereby markedly reducing interference from biological fluid matrices (such as trace hemolysis in serum and plasma). In this format, referred to as AlphaLISA, it provides an alternative technology to classical ELISA assays and is suitable for high throughput automated fluid dispensing and detection systems.

The Synergy HTX incorporates linear and orbital shaking and Four-Zone incubation to 50 degrees Celsius with condensation control to minimize plate lid condensation. These features, coupled with an available dual reagent dispenser, make the Synergy HTX an excellent platform for biochemical and cell-based applications such as nucleic acid quantification, cell growth and toxicity assays, kinetic ELISA, and inject/read assays.

The optional dual reagent injection system automates inject/read assays such as ion channels assays or flash luminescence assays (e.g., luciferase or ATP assays). The Synergy HTX’s modular design allows upgrading supported by BioTek’s Gen5 data analysis software for advanced reader control, data analysis, graphing, exporting, and reporting. Additionally, the instrument is compatible with BioTek’s Take3 Multi-Volume Microplate that measures up to 16 two microliter samples, two BioCells, or a standard cuvette for fast and simple multivolume, multisample analysis.

Related Links:

BioTek Instruments, Inc.


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The breakthrough could result in a higher success rate using a simple oral swab test before IVF (Photo courtesy of Shutterstock)

POC Oral Swab Test to Increase Chances of Pregnancy in IVF

Approximately 15% of couples of reproductive age experience involuntary childlessness. A significant reason for this is the growing trend of delaying family planning, a global shift that is expected to... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.